Less than 10% of people that would benefit from obesity jabs including Wegovy can access them, caution the World Health Organization as it publishes its first guidance on the therapies.
Given in excess of 1,000,000,000 individuals worldwide now living with obesity, it is advocating for increased and just availability to GLP-1 medication.
Per forecasts, more than two billion are projected to be obese by 2030 unless action is taken.
"The new guidelines affirms that obesity is a long-term condition that can be treated with holistic and ongoing care," stated its chief Tedros Adhanom Ghebreyesus.
High costs, constrained manufacturing, and distribution challenges are significant obstacles to universal availability to the jabs that can aid individuals in losing substantial body mass, explains the body.
GLP-1 Therapy Scarcity
Even under the present best projected outlook, the production of such drugs might only reach around 100 million people – fewer than 10% of the global need, according to the health organization.
The recommendation urges nations and manufacturers to increase access, via approaches such as licensing agreements.
Exclusive production rights on a key compound – the primary ingredient of Novo Nordisk's Wegovy – is due to expire in several nations in 2026.
How Weight-Loss Injections Function
The injections imitate a natural hormone to reduce digestion speed, suppress the appetite and enhance feelings of fullness so individuals consume fewer calories.
Individuals usually begin shedding pounds within a few weeks of commencing the regular doses.
Evidence suggests users may put most of the weight back on after a year of halting the treatment, as their normal food cravings resume.
Being carrying excess weight increases your chance for contracting diseases, like diabetes, heart disease, brain attack, and certain malignancies.
Excess weight affects people in all nations and was associated with over three and a half million deaths worldwide in 2024, as per the health agency.
